Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2023-10-10 Foreign Filer Report
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-10-10 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "NOUVEAU NOMBRE D'ACTIONS ET DE DROITS DE VOTE D'INNATE PHARMA AU 3 OCTOBRE 2023" and explicitly states it is published in accordance with French commercial code and AMF regulations (L. 233-8 II du Code de Commerce et 223-16 du règlement général de l'AMF). It details the total number of shares and voting rights as of a specific date. This type of mandatory disclosure regarding the total share capital and voting rights is a specific regulatory filing in France, often related to capital structure changes or mandatory periodic updates. While it relates to share capital, it is a notification of the current count, not an announcement of a transaction (POS) or a general capital change proposal (SHA). It is a specific regulatory disclosure concerning the structure of ownership/voting rights. Given the options, this is most closely related to a notification about share structure/capital, but since it is a mandatory regulatory disclosure about the number of shares/votes, it fits best under the general 'Regulatory Filings' (RNS) as a specific, non-standard report type, or potentially SHA if interpreted broadly as a capital structure update. However, since it is a routine, mandated disclosure of the current share count (not a buyback, issuance, or split announcement), RNS (Regulatory Filings) is the most appropriate general category for mandatory, non-financial periodic disclosures that don't fit elsewhere. It is not an Earnings Release (ER), Interim Report (IR), or a Director's Dealing (DIRS). It is a formal regulatory update on the share base.
2023-10-09 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states its purpose: to release the 'Total number of shares outstanding as well as its voting rights as at October 3, 2023,' citing compliance with the French Commercial Code and AMF regulations. This type of mandatory disclosure regarding the total number of shares and voting rights is a specific regulatory filing requirement, often related to capital structure changes or major shareholding notifications. Since it is a formal announcement detailing the exact count of shares and voting rights, it fits best under 'Major Shareholding Notification' (MRQ) as it directly relates to the denominator used for calculating shareholding thresholds, or potentially a general 'Regulatory Filing' (RNS). Given the specific nature of reporting the total share count based on regulatory requirements (AMF), MRQ is the most precise fit among the options, as these figures are crucial for tracking major ownership changes. It is not an earnings release (ER), an annual report (10-K), or a dividend notice (DIV).
2023-10-09 English
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-10-05 English
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is a press release dated October 5, 2023, providing an update on the clinical program for a drug called lacutamab, including recruitment status, expected data timelines (Q4 2023), and a partial clinical hold from the FDA. This type of announcement, which details operational and clinical progress, financial outlook snippets, and corporate news via a formal press release format, is characteristic of an Earnings Release (ER) or a general corporate update. Since it focuses on operational updates and clinical milestones rather than comprehensive financial statements (like a 10-K or IR) or just management changes (MANG), and it is an initial announcement of results/status updates, 'ER' (Earnings Release) is the most appropriate fit among the provided codes, as clinical updates often accompany or substitute for traditional quarterly earnings highlights for biotech firms. It is not a full report (10-K, IR), a transcript (CT), or a presentation (IP). Q4 2023
2023-10-05 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release dated October 5, 2023, from Innate Pharma, announcing updates regarding the clinical program for its drug candidate, lacutamab. It details the completion of recruitment for the Phase 2 TELLOMAK trial, expected data timelines (Q4 2023), and a partial clinical hold imposed by the FDA due to a serious adverse event. This type of announcement, focusing on clinical trial progress, regulatory interactions (FDA/EMA), and expected data releases, is characteristic of an Earnings Release (ER) or a general corporate update. Since it provides key financial/operational highlights (trial status, data timing) rather than the full, detailed financial statements of a quarterly report (IR) or the comprehensive management discussion (MDA), and it is a direct announcement of results/updates, 'ER' (Earnings Release) is the most appropriate classification, as these often include operational updates alongside financial context, or it could be classified as 'RNS' (Regulatory Filings) if it were purely regulatory news. Given the focus on clinical milestones and data expectations, ER is a strong fit for a biotech company's operational update press release. It is not a full report (10-K, IR), a presentation (IP), or a transcript (CT). FY 2023
2023-10-05 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.